AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PCVX

Wassil Jim sold $212K of PCVX

Wassil Jim (CHIEF OPERATING OFFICER) sold 3,477 shares of Vaxcyte, Inc. (PCVX) at an average of $61.07 ($60.89–$61.48, $0.21M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wassil Jim
Published Sep 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 7:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
high confidence
Mentioned
$PCVX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The disclosed insider sale is modest and pre‑arranged, offering little new insight for traders.

02

Market read

Routine insider transaction with minimal trading relevance.

03

What to watch

The sale follows a 10b5‑1 plan, reducing the likelihood of negative information.

Relevance 3/10Novelty 4/10Timing: post‑market filing on Sep 1

Background

Vaxcyte (PCVX) is a Nasdaq‑listed biotech developing vaccine technologies.

Company-level read

Ticker impact

$PCVXNeutralHigh confidence
Context

COO Wassil Jim sold 3,477 shares for $212K via a 10b5‑1 plan, reducing his stake to 155,041 shares.

Expected impact

No significant impact expected; price may stay flat.

Evidence & confidence

Sale size is small relative to market cap and disclosed via pre‑arranged plan, indicating no urgent information.

Market effects

Sector

None; Vaxcyte operates in biotech where insider sales are routine.

Regional

No regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

If the COO is reducing exposure, it could signal concerns about upcoming data.

Key entities

  • Officer
    Wassil Jim

    Chief Operating Officer of Vaxcyte

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety P

SEC EDGAR 8-K
$PCVXHighAI 8/10

Vaxcyte’s vaccine candidate met every main goal in a trial of 4,047 adults. More trial results are expected in 2027.

Vaxcyte's VAX-31 vaccine met all primary endpoints in a Phase 3 trial of 4,047 adults, showing safety and efficacy. The company plans to report more trial results in 2027 and submit a BLA in 2028. VAX-31 is designed to prevent pneumococcal disease. Vaxcyte also announced progress in its VAX-A1 vaccine candidate for Group A Streptococcus.

stocktitan.net
$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte reported Q3 2026 results, highlighting positive topline data from the OPUS-1 Phase 3 trial of VAX-31, meeting all primary endpoints. The company expects results from OPUS-2 and OPUS-3 trials in early 2027, supporting a BLA submission in 2028. Vaxcyte also announced progress in its VAX-31 infant indication and VAX-A1 Phase 1 study. As of September 30, 2026, the company had $3.4 billion in cash and investments.

globenewswire.com